Last reviewed · How we verify
XCEL-MC-ALPHA
At a glance
| Generic name | XCEL-MC-ALPHA |
|---|---|
| Also known as | Bone-marrow mesenchymal stromal cells |
| Sponsor | Banc de Sang i Teixits |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous Mesenchymal Stromal Cells for Multiple Sclerosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XCEL-MC-ALPHA CI brief — competitive landscape report
- XCEL-MC-ALPHA updates RSS · CI watch RSS
- Banc de Sang i Teixits portfolio CI